(NASDAQ: ACXP) Acurx Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Acurx Pharmaceuticals's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast ACXP's revenue for 2026 to be $4,411,989, with the lowest ACXP revenue forecast at $4,411,989, and the highest ACXP revenue forecast at $4,411,989. On average, 1 Wall Street analysts forecast ACXP's revenue for 2027 to be $55,780,141, with the lowest ACXP revenue forecast at $55,780,141, and the highest ACXP revenue forecast at $55,780,141.
In 2028, ACXP is forecast to generate $208,308,888 in revenue, with the lowest revenue forecast at $208,308,888 and the highest revenue forecast at $208,308,888.